HKSTP Park Company Eurekabio has raised an RMB 100M+ Series B round to advance its automated cell processing platform.
Congratulations! Eurekabio has raised an RMB 100M+ Series B round to advance its automated cell processing platform and the lentiviral vector production system developed by their team based at our Park.
Millions of people globally are suffering from different type of cancers. Our park company, Eurekabio, specialises in manufacturing supplies and platform for Cell and Gene Therapies (CGT).
Thank you Eurekabio for playing a pivotal role in accelerating the development of CGT through automation
Millions of people globally are suffering from different type of cancers. Our park company, Eurekabio, specialises in manufacturing supplies and platform for Cell and Gene Therapies (CGT).
Thank you Eurekabio for playing a pivotal role in accelerating the development of CGT through automation
- Standardising cell processing procedures
- Increasing efficiency
- Reducing human error and contamination
Learn more: https://lnkd.in/gEGmc7Vz
Follow our page for more fundraising news happening in our thriving ecosystem.
More Information : https://www.hkstp.org/what-we-offer/institute-for-translational-research-overview/
- Increasing efficiency
- Reducing human error and contamination
Learn more: https://lnkd.in/gEGmc7Vz
Follow our page for more fundraising news happening in our thriving ecosystem.
More Information : https://www.hkstp.org/what-we-offer/institute-for-translational-research-overview/